Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
Summary
“We are honored to have Polaris Partners, with its long history of leadership in biotechnology investing and company building, partner with us as we pursue novel drugs to treat cardiovascular diseases, and we are especially pleased to have Amy Schulman of Polaris bring her deep strategic and leadership experience to our board,” said Dr. Michael E. Mendelsohn, founder and chairman of Cardurion Pharmaceuticals. “Cardurion is dedicated to advancing novel mechanisms to create new treatments for cardiovascular diseases, which remain the greatest cause of morbidity and mortality in our society. Our lead clinical program studying CRD-733, a novel phosphodiesterase-9 enzyme (PDE9) inhibitor, is in development for the treatment of heart failure, which remains a major cause of death in our society. “This area of clear critical need, coupled with Michael’s deep expertise in the field, were important factors in Polaris’ decision to invest. Cardurion Pharmaceuticals is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases.